Payment overview · 2025
General Payments
$176.64
10 reported records · 6 companies
Healthcare provider profile · identity verified
Anne P Hooyer, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SIOUX CENTER, IA · NPI 1295797173
Verified facts
What the public records show
CMS Open Payments records show Anne P Hooyer, ARNP received $176.64 in general payments during 2025 across 10 reported records.
Verona Pharma, Inc. accounted for 34.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $60.53 | 34.3% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $49.92 | 28.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.15 | 12.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.90 | 9.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.27 | 8.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.87 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $176.64 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $60.53 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $49.92 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 588 | 113 |
| Omeprazole | Omeprazole | 495 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 447 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 445 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 395 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 70 |
| Losartan Potassium | Losartan Potassium | 269 | 55 |
| Celecoxib | Celecoxib | 261 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 56 |
| Lisinopril | Lisinopril | 248 | 61 |
| Lorazepam | Lorazepam | 238 | 45 |
| Mounjaro | Tirzepatide | 225 | 29 |
| Tramadol Hcl | Tramadol Hcl | 207 | 32 |
| Metformin Hcl Er | Metformin Hcl | 203 | 39 |
| Prednisone | Prednisone | 201 | 131 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 189 | 39 |
| Eliquis | Apixaban | 179 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 173 | 37 |
| Furosemide | Furosemide | 172 | 45 |
| Glipizide Er | Glipizide | 171 | 25 |
| Gabapentin | Gabapentin | 167 | 37 |
| Bupropion Xl | Bupropion Hcl | 154 | 25 |
| Pregabalin | Pregabalin | 152 | 21 |
| Carvedilol | Carvedilol | 136 | 21 |
| Montelukast Sodium | Montelukast Sodium | 124 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 21 |
| Allopurinol | Allopurinol | 109 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 28 |
| Mirtazapine | Mirtazapine | 96 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 22 |
| Warfarin Sodium | Warfarin Sodium | 93 | 12 |
| Spironolactone | Spironolactone | 90 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 87 | 16 |
| Metformin Hcl | Metformin Hcl | 82 | 13 |
| Simvastatin | Simvastatin | 77 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 14 |
| Trazodone Hcl | Trazodone Hcl | 76 | 19 |
| Azithromycin | Azithromycin | 74 | 61 |
| Cephalexin | Cephalexin | 72 | 52 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 70 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 22 |
| Valsartan | Valsartan | 64 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 61 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 13 |
| Cefdinir | Cefdinir | 60 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 56 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | 18 |
| Doxepin Hcl | Doxepin Hcl | 53 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Meloxicam | Meloxicam | 49 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 49 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Amoxicillin | Amoxicillin | 47 | 34 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 47 | 47 |
| Famotidine | Famotidine | 46 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 45 | 45 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Glipizide | Glipizide | 45 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 32 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 12 |
| Baclofen | Baclofen | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Trimethoprim | Trimethoprim | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $176.64 · 10 records | Verona Pharma, Inc. | EVENITY, Ohtuvayre, QULIPTA, UBRELVY, Veozah, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error